Intraperitoneal administration of docosahexaenoic acid for 14days increases serum unesterified DHA and seizure latency in the maximal pentylenetetrazol model

Epilepsy and Behavior

Volumn 33, Issue , 2014, Pages 138-143

  Trépanier, Marc Olivier ^a   Lim, Joonbum ^a   Lai, Terence K Y ^a   Cho, Hye Jin ^a   Domenichiello, Anthony F ^a   Chen, Chuck T ^a   Taha, Ameer Y ^a,b   Bazinet, Richard P ^a   Burnham, W M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Docosahexaenoic acid; Omega 3 polyunsaturated fatty acids; Pentylenetetrazol; Rat; Seizures

Indexed keywords

ALBUMIN; DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID ETHYL ESTER; PENTETRAZOLE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; IN VIVO STUDY; LATENT PERIOD; LIMIT OF DETECTION; LIPID ANALYSIS; NONHUMAN; RAT; SEIZURE THRESHOLD; TONIC CLONIC SEIZURE; TREATMENT DURATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; SEIZURES; WISTAR RAT;

ANIMALS; DOCOSAHEXAENOIC ACIDS; INJECTIONS, INTRAPERITONEAL; MALE; PENTYLENETETRAZOLE; RATS; RATS, WISTAR; SEIZURES;

EID: 84897871530     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.02.020     Document Type: Article

References (47)

1. Guberman A., Bruni J. Essentials of clinical epilepsy 1999, Butterworth-Heinemann, Boston. 2nd ed.
2. McHugh J.C., Delanty N. Epidemiology and classification of epilepsy: gender comparisons. Int Rev Neurobiol 2008, 83:11-26.
3. Burnham W.M. Antiseizure drugs. Principles of medical pharmacology 2007, 223-235. Saunders, Toronto. 7th ed. H. Kalant, D.M. Grant, J. Mitchell (Eds.).
4. Perucca P., Gilliam F.G. Adverse effects of antiepileptic drugs. Lancet Neurol 2012, 11:792-802.
5. Krivoy N., Taer M., Neuman M.G. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf 2006, 1:289-299.
6. Taha A.Y., Burnham W.M., Auvin S. Polyunsaturated fatty acids and epilepsy. Epilepsia 2010, 51:1348-1358.
7. Russo G.L. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 2009, 77:937-946.
8. Yavin E. Versatile roles of docosahexaenoic acid in the prenatal brain: from pro- and anti-oxidant features to regulation of gene expression. Prostaglandins Leukot Essent Fatty Acids 2006, 75:203-211.
9. Jones C.R., Arai T., Rapoport S.I. Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem Res 1997, 22:663-670.
10. Bazan N.G., Eady T.N., Khoutorova L., Atkins K.D., Hong S., Lu Y., et al. Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Exp Neurol 2012, 236:122-130.
11. Kang J.X., Leaf A. Evidence that free polyunsaturated fatty acids modify Na+channels by directly binding to the channel proteins. Proc Natl Acad Sci U S A 1996, 93:3542-3546.
12. Kang J.X., Xiao Y.F., Leaf A. Free, long-chain, polyunsaturated fatty acids reduce membrane electrical excitability in neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 1995, 92:3997-4001.
13. Vreugdenhil M., Bruehl C., Voskuyl R.A., Kang J.X., Leaf A., Wadman W.J. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci U S A 1996, 93:12559-12563.
14. Xiao Y., Li X. Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 1999, 846:112-121.
15. Young C., Gean P.W., Chiou L.C., Shen Y.Z. Docosahexaenoic acid inhibits synaptic transmission and epileptiform activity in the rat hippocampus. Synapse 2000, 37:90-94.
16. Taha A.Y., Zahid T., Epps T., Trepanier M.O., Burnham W.M., Bazinet R.P., Zhang L. Selective reduction of excitatory hippocampal sharp waves by docosahexaenoic acid and its methyl ester analog ex-vivo. Brain Res 2013, 1537:9-17.
17. Yehuda S., Carasso R.L., Mostofsky D.I. Essential fatty acid preparation (SR-3) raises the seizure threshold in rats. Eur J Pharmacol 1994, 254:193-198.
18. Taha A.Y., Baghiu B.M., Lui R., Nylen K., Ma D.W., Burnham W.M. Lack of benefit of linoleic and alpha-linolenic polyunsaturated fatty acids on seizure latency, duration, severity or incidence in rats. Epilepsy Res 2006, 71:40-46.
19. Taha A.Y., Filo E., Ma D.W., McIntyre Burnham W. Dose-dependent anticonvulsant effects of linoleic and alpha-linolenic polyunsaturated fatty acids on pentylenetetrazol induced seizures in rats. Epilepsia 2009, 50:72-82.
20. Voskuyl R.A., Vreugdenhil M., Kang J.X., Leaf A. Anticonvulsant effect of polyunsaturated fatty acids in rats, using the cortical stimulation model. Eur J Pharmacol 1998, 341:145-152.
21. Musto A.E., Gjorstrup P., Bazan N.G. The omega-3 fatty acid-derived neuroprotectin D1 limits hippocampal hyperexcitability and seizure susceptibility in kindling epileptogenesis. Epilepsia 2011, 52:1601-1608.
22. Taha A.Y., Jeffrey M.A., Taha N.M., Bala S., Burnham W.M. Acute administration of docosahexaenoic acid increases resistance to pentylenetetrazol-induced seizures in rats. Epilepsy Behav 2010, 17:336-343.
23. Trepanier M.O., Taha A.Y., Mantha R.L., Ciobanu F.A., Zeng Q.H., Tchkhartichvili G.M., et al. Increases in seizure latencies induced by subcutaneous docosahexaenoic acid are lost at higher doses. Epilepsy Res 2012, 99:225-232.
24. Bazan N.G. Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain. Biochim Biophys Acta 1970, 218:1-10.
25. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
26. Rabinovitz S., Mostofsky D.I., Yehuda S. Anticonvulsant efficiency, behavioral performance and cortisol levels: a comparison of carbamazepine (CBZ) and a fatty acid compound (SR-3). Psychoneuroendocrinology 2004, 29:113-124.
27. Yehuda S., Brandys Y., Blumenfeld A., Mostofsky D.I. Essential fatty acid preparation reduces cholesterol and fatty acids in rat cortex. Int J Neurosci 1996, 86:249-256.
28. Taha A.Y., Alizadeh S., Zeng Q.H., Filo E., McPherson J.P., Burnham W.M. Assessing the metabolic and toxic effects of anticonvulsant doses of polyunsaturated fatty acids on the liver in rats. J Toxicol Environ Health A 2009, 72:1191-1200.
29. Song B.J., Elbert A., Rahman T., Orr S.K., Chen C.T., Febbraio M., et al. Genetic ablation of CD36 does not alter mouse brain polyunsaturated fatty acid concentrations. Lipids 2010, 45:291-299.
30. Chen C.T., Ma D.W., Kim J.H., Mount H.T., Bazinet R.P. The low density lipoprotein receptor is not necessary for maintaining mouse brain polyunsaturated fatty acid concentrations. J Lipid Res 2008, 49:147-152.
31. Ouellet M., Emond V., Chen C.T., Julien C., Bourasset F., Oddo S., et al. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem Int 2009, 55:476-482.
32. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 2001, 77:796-803.
33. Taha A.Y., Trepanier M.O., Ciobanu F.A., Taha N.M., Ahmed M., Zeng Q., et al. A minimum of 3months of dietary fish oil supplementation is required to raise amygdaloid afterdischarge seizure thresholds in rats - implications for treating complex partial seizures. Epilepsy Behav 2013, 27:49-58.
34. Gilby K.L., Jans J., McIntyre D.C. Chronic omega-3 supplementation in seizure-prone versus seizure-resistant rat strains: a cautionary tale. Neuroscience 2009, 163:750-758.
35. Bandero C.R., Salvadori M.G., Gomes A.T., Dal Ri N.M., Furian A.F., Oliveira M.S., et al. Fish oil attenuates methylmalonate-induced seizures. Epilepsy Res 2013, 105:69-76.
36. Mansbach C.M., Siddiqi S.A. The biogenesis of chylomicrons. Annu Rev Physiol 2010, 72:315-333.
37. Tso P., Balint J.A. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am J Physiol 1986, 250:G715-G726.
38. Mayes P.A., Botham K.M. Lipid Transport & Storage. Harper's Illustrated Biochemistry 2003, 205-218. McGraw-Hill, New York. 26th ed. R.K. Murray, D.K. Granner, P.A. Mayes, V.W. Rodwell (Eds.).
39. Pihl A., Block K., Anker H.S. The rates of synthesis of fatty acids and cholesterol in the adult rat studied with the aid of labeled acetic acid. J Biol Chem 1950, 183:10.
40. Willis S., Samala R., Rosenberger T.A., Borges K. Eicosapentaenoic and docosahexaenoic acids are not anticonvulsant or neuroprotective in acute mouse seizure models. Epilepsia 2009, 50:138-142.
41. Yuen A.W., Flugel D., Poepel A., Bell G.S., Peacock J.L., Sander J.W. Non-randomized open trial of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic epilepsy. Epilepsy Behav 2012, 23:370-372.
42. Yuen A.W., Sander J.W., Flugel D., Patsalos P.N., Browning L., Bell G.S., et al. Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations?. Epilepsy Behav 2008, 12:317-323.
43. Bromfield E., Dworetzky B., Hurwitz S., Eluri Z., Lane L., Replansky S., et al. A randomized trial of polyunsaturated fatty acids for refractory epilepsy. Epilepsy Behav 2008, 12:187-190.
44. DeGiorgio C.M., Miller P., Meymandi S., Gornbein J.A. n-3 fatty acids (fish oil) for epilepsy, cardiac risk factors, and risk of SUDEP: clues from a pilot, double-blind, exploratory study. Epilepsy Behav 2008, 13:681-684.
45. Schlanger S., Shinitzky M., Yam D. Diet enriched with omega-3 fatty acids alleviates convulsion symptoms in epilepsy patients. Epilepsia 2002, 43:103-104.
46. Al Khayat H.A., Awadalla M.M., Al Wakad A., Marzook Z.A. Polyunsaturated fatty acids in children with idiopathic intractable epilepsy: serum levels and therapeutic response. J Pediatr Neurol 2010, 8:175-185.
47. Yuen A.W., Sander J.W., Fluegel D., Patsalos P.N., Bell G.S., Johnson T., et al. Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behav 2005, 7:253-258.